Imaging genetics: implications for research on variable antidepressant drug response

References

• Wong ML, Licinio J. Research and treatment approaches to depression. Nat. Rev. Neurosci.2(5), 343–351 (2001).
   PubMed Web of Science ®Google Scholar
• Melander H, Salmonson T, Abadie E, Van Zwieten-Boot B. A regulatory apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur. Neuropsychopharmacol.18(9), 623–627 (2008).
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet373(9665), 746–758 (2009).
   PubMed Web of Science ®Google Scholar
• Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med.5(2), e45 (2008).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry163(1), 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ331(7509), 155–157 (2005).
   PubMed Web of Science ®Google Scholar
• Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin. Lab. Med.28(4), 619–626 (2008).
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N. Engl. J. Med.348(6), 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nat. Rev. Drug Discov.1(1), 37–44 (2002).
   PubMed Web of Science ®Google Scholar
• Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry15(5), 473–500 (2008).
   PubMed Web of Science ®Google Scholar
• Schosser A, Kasper S. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int. Clin. Psychopharmacol.24(6), 277–288 (2009).
   PubMed Web of Science ®Google Scholar
• Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol. Ther.124(1), 57–73 (2009).
   PubMed Web of Science ®Google Scholar
• Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr. Bull.34(6), 1130–1144 (2008).
   PubMed Web of Science ®Google Scholar
• Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nat. Rev. Neurosci.9(8), 638–646 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson IM, Mckie S, Elliott R, Williams SR, Deakin JF. Assessing human 5-ht function in vivo with pharmacoMRI. Neuropharmacology55(6), 1029–1037 (2008).
   PubMedGoogle Scholar
• Scharinger C, Rabl U, Sitte HH, Pezawas L. Imaging genetics of mood disorders. Neuroimage DOI: doi:10.1016/j.neuroimage.2010.02.019 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience164(1), 300–330 (2009).
   PubMed Web of Science ®Google Scholar
• Logothetis NK. The ins and outs of fMRI signals. Nat. Neurosci.10(10), 1230–1232 (2007).
   PubMedGoogle Scholar
• Raichle ME, Snyder AZ. A default mode of brain function: a brief history of an evolving idea. Neuroimage37(4), 1083–1090 (2007).
   PubMed Web of Science ®Google Scholar
• Poldrack RA, Fletcher PC, Henson RN, Worsley KJ, Brett M, Nichols TE. Guidelines for reporting an fMRI study. Neuroimage40(2), 409–414 (2008).
   PubMed Web of Science ®Google Scholar
• Bandettini PA. What’s new in neuroimaging methods? Ann. N. Y. Acad. Sci.1156, 260–293 (2009).
   PubMed Web of Science ®Google Scholar
• Ashburner J, Friston KJ. Voxel-based morphometry – the methods. Neuroimage11(6 Pt 1), 805–821 (2000).
   PubMed Web of Science ®Google Scholar
• Ridgway GR, Henley SM, Rohrer JD, Scahill RI, Warren JD, Fox NC. Ten simple rules for reporting voxel-based morphometry studies. Neuroimage40(4), 1429–1435 (2008).
   PubMedGoogle Scholar
• Sexton CE, Mackay CE, Ebmeier KP. A systematic review of diffusion tensor imaging studies in affective disorders. Biol. Psychiatry66(9), 814–823 (2009).
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A. Neural connectivity as an intermediate phenotype: brain networks under genetic control. Hum. Brain Mapp.30(7), 1938–1946 (2009).
   PubMedGoogle Scholar
• Ledoux J. The amygdala. Curr. Biol.17(20), R868–R874 (2007).
   Web of Science ®Google Scholar
• Anand A, Shekhar A. Brain imaging studies in mood and anxiety disorders: special emphasis on the amygdala. Ann. N. Y. Acad. Sci.985, 370–388 (2003).
   PubMed Web of Science ®Google Scholar
• Sehlmeyer C, Schoning S, Zwitserlood P et al. Human fear conditioning and extinction in neuroimaging: a systematic review. PLoS ONE4(6), E5865 (2009).
   PubMed Web of Science ®Google Scholar
• Mckie S, Del-Ben C, Elliott R et al. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl.)180(4), 680–686 (2005).
   PubMedGoogle Scholar
• Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology33(13), 3221–3225 (2008).
   PubMedGoogle Scholar
• Del-Ben CM, Deakin JF, Mckie S et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study. Neuropsychopharmacology30(9), 1724–1734 (2005).
   PubMed Web of Science ®Google Scholar
• Bhagwagar Z, Cowen PJ, Goodwin GM, Harmer CJ. Normalization of enhanced fear recognition by acute ssri treatment in subjects with a previous history of depression. Am. J. Psychiatry161(1), 166–168 (2004).
   PubMed Web of Science ®Google Scholar
• Browning M, Reid C, Cowen PJ, Goodwin GM, Harmer CJ. A single dose of citalopram increases fear recognition in healthy subjects. J. Psychopharmacol.21(7), 684–690 (2007).
   PubMed Web of Science ®Google Scholar
• Hetrick S, Merry S, Mckenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (ssris) for depressive disorders in children and adolescents. Cochrane Database Syst. Rev. (3), CD004851 (2007).
   Google Scholar
• Burghardt NS, Sullivan GM, Mcewen BS, Gorman JM, Ledoux JE. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol. Psychiatry55(12), 1171–1178 (2004).
   PubMed Web of Science ®Google Scholar
• Burghardt NS, Bush DE, Mcewen BS, Ledoux JE. Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2c) receptor antagonist. Biol. Psychiatry62(10), 1111–1118 (2007).
   PubMed Web of Science ®Google Scholar
• Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am. J. Psychiatry161(7), 1256–1263 (2004).
   PubMed Web of Science ®Google Scholar
• Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol. Psychiatry59(9), 816–820 (2006).
   PubMed Web of Science ®Google Scholar
• Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl.)196(4), 661–672 (2008).
   PubMed Web of Science ®Google Scholar
• Windischberger C, Lanzenberger R, Holik A et al. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage49(2), 1161–1170 (2010).
   PubMed Web of Science ®Google Scholar
• Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using pet measures of regional glucose metabolism. Eur. Neuropsychopharmacol.12(6), 527–544 (2002).
   PubMed Web of Science ®Google Scholar
• Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch. Gen. Psychiatry62(3), 282–288 (2005).
   PubMed Web of Science ®Google Scholar
• Fu CH, Williams SC, Cleare AJ et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch. Gen. Psychiatry61(9), 877–889 (2004).
   PubMed Web of Science ®Google Scholar
• Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol. Psychiatry50(9), 651–658 (2001).
   PubMed Web of Science ®Google Scholar
• Anand A, Li Y, Wang Y, Gardner K, Lowe MJ. Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an fMRI study. J. Neuropsychiatry Clin. Neurosci.19(3), 274–282 (2007).
   PubMed Web of Science ®Google Scholar
• Robertson B, Wang L, Diaz MT et al. Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. J. Clin. Psychiatry68(2), 261–267 (2007).
   PubMed Web of Science ®Google Scholar
• Mcclure EB, Adler A, Monk CS et al. FMRI predictors of treatment outcome in pediatric anxiety disorders. Psychopharmacology (Berl.)191(1), 97–105 (2007).
   PubMed Web of Science ®Google Scholar
• Canli T, Cooney RE, Goldin P et al. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport16(12), 1267–1270 (2005).
   PubMed Web of Science ®Google Scholar
• Dannlowski U, Ohrmann P, Bauer J et al. 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacology33(2), 418–424 (2008).
   PubMed Web of Science ®Google Scholar
• Vogt BA. Cingulate Neurobiology and Disease. Oxford University Press, London, UK (2009).
   Google Scholar
• Drevets WC, Price JL, Simpson JR Jr. et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature386(6627), 824–827 (1997).
   PubMed Web of Science ®Google Scholar
• Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl Acad. Sci. USA95(22), 13290–13295 (1998).
   PubMed Web of Science ®Google Scholar
• Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci.4(12), 1002–1012 (2003).
   PubMed Web of Science ®Google Scholar
• Kranz GS, Kasper S, Lanzenberger R. Reward and the serotonergic system. Neuroscience166(4), 1023–1035 (2010).
   PubMedGoogle Scholar
• Rose EJ, Simonotto E, Spencer EP, Ebmeier KP. The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task. Psychopharmacology (Berl.)185(3), 339–347 (2006).
   PubMed Web of Science ®Google Scholar
• Brody AL, Saxena S, Stoessel P et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch. Gen. Psychiatry58(7), 631–640 (2001).
   PubMed Web of Science ®Google Scholar
• Goldapple K, Segal Z, Garson C et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch. Gen. Psychiatry61(1), 34–41 (2004).
   PubMed Web of Science ®Google Scholar
• Bauer M, London ED, Rasgon N et al. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol. Psychiatry10(5), 456–469 (2005).
   PubMed Web of Science ®Google Scholar
• Mayberg HS, Brannan SK, Mahurin RK et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport8(4), 1057–1061 (1997).
   PubMed Web of Science ®Google Scholar
• Mayberg HS, Brannan SK, Tekell JL et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry48(8), 830–843 (2000).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Konarski JZ, Segal ZV et al. Differences in brain glucose metabolism between responders to cbt and venlafaxine in a 16-week randomized controlled trial. Am. J. Psychiatry164(5), 778–788 (2007).
   PubMed Web of Science ®Google Scholar
• Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am. J. Psychiatry160(1), 64–75 (2003).
   PubMed Web of Science ®Google Scholar
• Chen CH, Ridler K, Suckling J et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol. Psychiatry62(5), 407–414 (2007).
   PubMed Web of Science ®Google Scholar
• Costafreda SG, Chu C, Ashburner J, Fu CH. Prognostic and diagnostic potential of the structural neuroanatomy of depression. PLoS ONE4(7), E6353 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh ND, Williams SC, Brammer MJ et al. A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol. Psychiatry62(11), 1236–1243 (2007).
   PubMed Web of Science ®Google Scholar
• Rolls ET, Grabenhorst F. The orbitofrontal cortex and beyond: from affect to decision-making. Prog. Neurobiol.86(3), 216–244 (2008).
   PubMed Web of Science ®Google Scholar
• Rushworth MF, Behrens TE, Rudebeck PH, Walton ME. Contrasting roles for cingulate and orbitofrontal cortex in decisions and social behaviour. Trends Cogn. Sci.11(4), 168–176 (2007).
   PubMed Web of Science ®Google Scholar
• Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct.213(1–2), 93–118 (2008).
   PubMed Web of Science ®Google Scholar
• Mccabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol. Psychiatry67(5), 439–445
   PubMedGoogle Scholar
• Brody AL, Saxena S, Silverman DH et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res.91(3), 127–139 (1999).
   PubMed Web of Science ®Google Scholar
• Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: the neural basis of normal emotion perception. Biol. Psychiatry54(5), 504–514 (2003).
   PubMed Web of Science ®Google Scholar
• Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol. Psychiatry54(5), 515–528 (2003).
   PubMed Web of Science ®Google Scholar
• Koolschijn PC, Van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum. Brain Mapp.30(11), 3719–3735 (2009).
   PubMed Web of Science ®Google Scholar
• Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am. J. Psychiatry161(11), 1957–1966 (2004).
   PubMed Web of Science ®Google Scholar
• Mcewen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann. N. Y. Acad. Sci.933, 265–277 (2001).
   PubMed Web of Science ®Google Scholar
• Kasper S, Mcewen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs22(1), 15–26 (2008).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Evans KR, Kruger S et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry158(6), 899–905 (2001).
   PubMed Web of Science ®Google Scholar
• Aihara M, Ida I, Yuuki N et al. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res.155(3), 245–256 (2007).
   PubMed Web of Science ®Google Scholar
• Fu CH, Williams SC, Brammer MJ et al. Neural responses to happy facial expressions in major depression following antidepressant treatment. Am. J. Psychiatry164(4), 599–607 (2007).
   PubMed Web of Science ®Google Scholar
• Macqueen GM, Yucel K, Taylor VH, Macdonald K, Joffe R. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol. Psychiatry64(10), 880–883 (2008).
   PubMed Web of Science ®Google Scholar
• Frodl T, Jager M, Smajstrlova I et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J. Psychiatry Neurosci.33(5), 423–430 (2008).
   PubMed Web of Science ®Google Scholar
• Kronmuller KT, Pantel J, Kohler S et al. Hippocampal volume and 2-year outcome in depression. Br. J. Psychiatry192(6), 472–473 (2008).
   PubMed Web of Science ®Google Scholar
• Vakili K, Pillay SS, Lafer B et al. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol. Psychiatry47(12), 1087–1090 (2000).
   PubMed Web of Science ®Google Scholar
• Frodl TS, Koutsouleris N, Bottlender R et al. Depression-related variation in brain morphology over 3 years: effects of stress? Arch. Gen. Psychiatry65(10), 1156–1165 (2008).
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat. Neurosci.10(9), 1116–1124 (2007).
   PubMed Web of Science ®Google Scholar
• Wang F, Kalmar JH, He Y et al. Functional and structural connectivity between the perigenual anterior cingulate and amygdala in bipolar disorder. Biol. Psychiatry66(5), 516–521 (2009).
   PubMed Web of Science ®Google Scholar
• Anand A, Li Y, Wang Y et al. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol. Psychiatry57(10), 1079–1088 (2005).
   PubMed Web of Science ®Google Scholar
• Pezawas L, Meyer-Lindenberg A, Drabant EM et al.5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat. Neurosci.8(6), 828–834 (2005).
   PubMed Web of Science ®Google Scholar
• Chen CH, Suckling J, Ooi C et al. Functional coupling of the amygdala in depressed patients treated with antidepressant medication. Neuropsychopharmacology33(8), 1909–1918 (2008).
   PubMed Web of Science ®Google Scholar
• Cremers HR, Demenescu LR, Aleman A et al. Neuroticism modulates amygdala–prefrontal connectivity in response to negative emotional facial expressions. Neuroimage49(1), 963–970 (2010).
   PubMed Web of Science ®Google Scholar
• Kim MJ, Whalen PJ. The structural integrity of an amygdala–prefrontal pathway predicts trait anxiety. J. Neurosci.29(37), 11614–11618 (2009).
   PubMed Web of Science ®Google Scholar
• Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev.40(2), 187–224 (2008).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Seeringer A, Godoy AL et al. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol. Psychiatry DOI: 10.1038/mp.2010.42 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry3(1), 5–43 (2002).
   PubMedGoogle Scholar
• Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem.66(6), 2621–2624 (1996).
   PubMed Web of Science ®Google Scholar
• Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science274(5292), 1527–1531 (1996).
   PubMed Web of Science ®Google Scholar
• Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science301(5631), 386–389 (2003).
   PubMed Web of Science ®Google Scholar
• Kunugi H, Hattori M, Kato T et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol. Psychiatry2(6), 457–462 (1997).
   PubMed Web of Science ®Google Scholar
• Canli T, Lesch KP. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat. Neurosci.10(9), 1103–1109 (2007).
   PubMed Web of Science ®Google Scholar
• Kalbitzer J, Frokjaer VG, Erritzoe D et al. The personality trait openness is related to cerebral 5-HTT levels. Neuroimage45(2), 280–285 (2009).
   PubMed Web of Science ®Google Scholar
• Praschak-Rieder N, Kennedy J, Wilson AA et al. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)c] DASB positron emission tomography study. Biol. Psychiatry62(4), 327–331 (2007).
   PubMed Web of Science ®Google Scholar
• Reimold M, Smolka MN, Schumann G et al. Midbrain serotonin transporter binding potential measured with [11c]DASB is affected by serotonin transporter genotype. J. Neural. Transm.114(5), 635–639 (2007).
   PubMed Web of Science ®Google Scholar
• Parsey RV, Hastings RS, Oquendo MA et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am. J. Psychiatry163(1), 48–51 (2006).
   PubMed Web of Science ®Google Scholar
• Murthy NV, Selvaraj S, Cowen PJ et al. Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [(11)c] DASB binding in the living human brain. Neuroimage52(1), 50–54 (2010).
   PubMed Web of Science ®Google Scholar
• Van Dyck CH, Malison RT, Staley JK et al. Central serotonin transporter availability measured with [123i]β-CIT SPECT in relation to serotonin transporter genotype. Am. J. Psychiatry161(3), 525–531 (2004).
   PubMed Web of Science ®Google Scholar
• Shioe K, Ichimiya T, Suhara T et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by pet. Synapse48(4), 184–188 (2003).
   PubMed Web of Science ®Google Scholar
• Mann JJ, Huang YY, Underwood MD et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR ) and prefrontal cortical binding in major depression and suicide. Arch. Gen. Psychiatry57(8), 729–738 (2000).
   PubMed Web of Science ®Google Scholar
• Kalbitzer J, Erritzoe D, Holst KK et al. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol. Psychiatry67(11), 1033–1039 (2010).
   PubMedGoogle Scholar
• Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci.32(2), 86–102 (2007).
   PubMed Web of Science ®Google Scholar
• Sibille E, Lewis DA. Sert-ainly involved in depression, but when? Am. J. Psychiatry163(1), 8–11 (2006).
   PubMedGoogle Scholar
• Homberg JR, Schubert D, Gaspar P. New perspectives on the neurodevelopmental effects of ssris. Trends Pharmacol. Sci.31(2), 60–65 (2010).
   PubMed Web of Science ®Google Scholar
• Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science306(5697), 879–881 (2004).
   PubMed Web of Science ®Google Scholar
• Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR ) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry12(3), 247–257 (2007).
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry3(6), 508–511 (1998).
   PubMed Web of Science ®Google Scholar
• Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIS response in mood disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet.129B(1), 36–40 (2004).
   PubMed Web of Science ®Google Scholar
• Kato M, Ikenaga Y, Wakeno M et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int. Clin. Psychopharmacol.20(3), 151–156 (2005).
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Wakeno M et al. Effects of the serotonin type 2a, 3a and 3b receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed japanese patients. Neuropsychobiology53(4), 186–195 (2006).
   PubMed Web of Science ®Google Scholar
• Zanardi R, Serretti A, Rossini D et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry50(5), 323–330 (2001).
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology23(5), 587–590 (2000).
   PubMed Web of Science ®Google Scholar
• Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol.20(1), 105–107 (2000).
   PubMed Web of Science ®Google Scholar
• Murphy Gm JR, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry61(11), 1163–1169 (2004).
   PubMed Web of Science ®Google Scholar
• Bozina N, Peles AM, Sagud M, Bilusic H, Jakovljevic M. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J. Biol. Psychiatry9(3), 190–197 (2008).
   PubMed Web of Science ®Google Scholar
• Rausch JL, Johnson ME, Fei YJ et al. Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome. Biol. Psychiatry51(9), 723–732 (2002).
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry7(10), 1115–1119 (2002).
   PubMed Web of Science ®Google Scholar
• Joyce PR, Mulder RT, Luty SE et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and γ protein β3 subunit as predictors of response to fluoxetine and nortriptyline. Int. J. Neuropsychopharmacol.6(4), 339–346 (2003).
   PubMed Web of Science ®Google Scholar
• Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (c-1019g) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J.6(1), 27–33 (2006).
   PubMed Web of Science ®Google Scholar
• Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L: 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J. Clin. Psychopharmacol.23(6), 563–567 (2003).
   PubMed Web of Science ®Google Scholar
• Huezo-Diaz P, Uher R, Smith R et al. Moderation of antidepressant response by the serotonin transporter gene. Br. J. Psychiatry195(1), 30–38 (2009).
   PubMed Web of Science ®Google Scholar
• Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl.)174(4), 525–529 (2004).
   PubMed Web of Science ®Google Scholar
• Lee MS, Lee HY, Lee HJ, Ryu SH. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr. Genet.14(2), 111–115 (2004).
   PubMed Web of Science ®Google Scholar
• Wilkie MJ, Smith G, Day RK et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J.9(1), 61–70 (2009).
   PubMed Web of Science ®Google Scholar
• Kim DK, Lim SW, Lee S et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport11(1), 215–219 (2000).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Ito K, Sato K et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in japanese depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry26(2), 383–386 (2002).
   PubMed Web of Science ®Google Scholar
• Kang RH, Wong ML, Choi MJ, Paik JW, Lee MS. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry31(6), 1317–1321 (2007).
   PubMed Web of Science ®Google Scholar
• Kim H, Lim SW, Kim S et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA296(13), 1609–1618 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Takahashi H, Higuchi H et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am. J. Psychiatry161(9), 1575–1580 (2004).
   PubMed Web of Science ®Google Scholar
• Dogan O, Yuksel N, Ergun MA et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet. Test12(2), 225–231 (2008).
   PubMedGoogle Scholar
• Kraft JB, Slager SL, Mcgrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol. Psychiatry58(5), 374–381 (2005).
   PubMed Web of Science ®Google Scholar
• Hu XZ, Rush AJ, Charney D et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry64(7), 783–792 (2007).
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Rush AJ, Biernacka JM et al. Slc6a4 variation and citalopram response. Am. J. Med. Genet. B Neuropsychiatr. Genet.150B(3), 341–351 (2009).
   PubMed Web of Science ®Google Scholar
• Maron E, Tammiste A, Kallassalu K et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur. Neuropsychopharmacol.19(6), 451–456 (2009).
   PubMed Web of Science ®Google Scholar
• Minov C, Baghai TC, Schule C et al. Serotonin-2α-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci. Lett.303(2), 119–122 (2001).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J. A 40-basepair vntr polymorphism in the dopamine transporter (dat1 ) gene and the rapid response to antidepressant treatment. Pharmacogenomics J.7(1), 48–55 (2007).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Mischoulon D, Smoller JW et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry54(9), 879–883 (2003).
   PubMed Web of Science ®Google Scholar
• Popp J, Leucht S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy – a pilot study. Pharmacogenomics7(2), 159–166 (2006).
   PubMed Web of Science ®Google Scholar
• Smits K, Smits L, Peeters F et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol.22(3), 137–143 (2007).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Yoshida K, Ito K et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur. Neuropsychopharmacol.12(5), 477–481 (2002).
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. Association study of two serotonin 1a receptor gene polymorphisms and fluoxetine treatment response in chinese major depressive disorders. Eur. Neuropsychopharmacol.16(7), 498–503 (2006).
   PubMed Web of Science ®Google Scholar
• Tanaka M, Kobayashi D, Murakami Y et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3b receptor gene and paroxetine-induced nausea. Int. J. Neuropsychopharmacol.11(2), 261–267 (2008).
   PubMed Web of Science ®Google Scholar
• Ogilvie AD, Battersby S, Bubb VJ et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet347(9003), 731–733 (1996).
   PubMed Web of Science ®Google Scholar
• Hu XZ, Lipsky RH, Zhu G et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet.78(5), 815–826 (2006).
   PubMed Web of Science ®Google Scholar
• Hranilovic D, Stefulj J, Schwab S et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol. Psychiatry55(11), 1090–1094 (2004).
   PubMed Web of Science ®Google Scholar
• Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry9(5), 433–441 (2004).
   PubMed Web of Science ®Google Scholar
• Andersen J, Taboureau O, Hansen KB et al. Location of the antidepressant binding site in the serotonin transporter: importance of ser-438 in recognition of citalopram and tricyclic antidepressants. J. Biol. Chem.284(15), 10276–10284 (2009).
   PubMed Web of Science ®Google Scholar
• Tavoulari S, Forrest LR, Rudnick G. Fluoxetine (prozac) binding to serotonin transporter is modulated by chloride and conformational changes. J. Neurosci.29(30), 9635–9643 (2009).
   PubMed Web of Science ®Google Scholar
• Brown SM, Hariri AR. Neuroimaging studies of serotonin gene polymorphisms: exploring the interplay of genes, brain, and behavior. Cogn. Affect. Behav. Neurosci.6(1), 44–52 (2006).
   PubMed Web of Science ®Google Scholar
• Munafo MR, Brown SM, Hariri AR. Serotonin transporter (5-HTTLPR ) genotype and amygdala activation: a meta-analysis. Biol. Psychiatry63(9), 852–857 (2008).
   PubMed Web of Science ®Google Scholar
• Hariri AR, Drabant EM, Munoz KE et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch. Gen. Psychiatry62(2), 146–152 (2005).
   PubMed Web of Science ®Google Scholar
• Bertolino A, Arciero G, Rubino V et al. Variation of human amygdala response during threatening stimuli as a function of 5´HTTLPR genotype and personality style. Biol. Psychiatry57(12), 1517–1525 (2005).
   PubMed Web of Science ®Google Scholar
• Canli T, Omura K, Haas BW, Fallgatter A, Constable RT, Lesch KP. Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. Proc. Natl Acad. Sci. USA102(34), 12224–12229 (2005).
   PubMed Web of Science ®Google Scholar
• Canli T, Qiu M, Omura K et al. Neural correlates of epigenesis. Proc. Natl Acad. Sci. USA103(43), 16033–16038 (2006).
   PubMed Web of Science ®Google Scholar
• Friedel E, Schlagenhauf F, Sterzer P et al.5-HTT genotype effect on prefrontal-amygdala coupling differs between major depression and controls. Psychopharmacology (Berl.)205(2), 261–271 (2009).
   PubMed Web of Science ®Google Scholar
• Dannlowski U, Konrad C, Kugel H et al. Emotion specific modulation of automatic amygdala responses by 5-HTTLPR genotype. Neuroimage DOI: 10.1016 (2009).
   Google Scholar
• Hariri AR, Mattay VS, Tessitore A et al. Serotonin transporter genetic variation and the response of the human amygdala. Science297(5580), 400–403 (2002).
   PubMed Web of Science ®Google Scholar
• Heinz A, Braus DF, Smolka MN et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat. Neurosci.8(1), 20–21 (2005).
   PubMed Web of Science ®Google Scholar
• Rao H, Gillihan SJ, Wang J et al. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol. Psychiatry62(6), 600–606 (2007).
   PubMed Web of Science ®Google Scholar
• Smolka MN, Buhler M, Schumann G et al. Gene–gene effects on central processing of aversive stimuli. Mol. Psychiatry12(3), 307–317 (2007).
   PubMed Web of Science ®Google Scholar
• Williams LM, Gatt JM, Schofield PR, Olivieri G, Peduto A, Gordon E. ‘Negativity bias’ in risk for depression and anxiety: brain-body fear circuitry correlates, 5-HTT-LPR and early life stress. Neuroimage47(3), 804–814 (2009).
   PubMed Web of Science ®Google Scholar
• Dannlowski U, Ohrmann P, Bauer J et al. Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav.6(7), 672–676 (2007).
   PubMed Web of Science ®Google Scholar
• Graff-Guerrero A, De La Fuente-Sandoval C, Camarena B et al. Frontal and limbic metabolic differences in subjects selected according to genetic variation of the SLC6A4 gene polymorphism. Neuroimage25(4), 1197–1204 (2005).
   PubMed Web of Science ®Google Scholar
• Fukudo S, Kanazawa M, Mizuno T et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage47(3), 946–951 (2009).
   PubMed Web of Science ®Google Scholar
• Passamonti L, Cerasa A, Gioia MC et al. Genetically dependent modulation of serotonergic inactivation in the human prefrontal cortex. Neuroimage40(3), 1264–1273 (2008).
   PubMed Web of Science ®Google Scholar
• Roiser JP, De Martino B, Tan GC et al. A genetically mediated bias in decision making driven by failure of amygdala control. J. Neurosci.29(18), 5985–5991 (2009).
   PubMed Web of Science ®Google Scholar
• Shah MP, Wang F, Kalmar JH et al. Role of variation in the serotonin transporter protein gene (SLC6A4 ) in trait disturbances in the ventral anterior cingulate in bipolar disorder. Neuropsychopharmacology34(5), 1301–1310 (2009).
   PubMedGoogle Scholar
• Frodl T, Koutsouleris N, Bottlender R et al. Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Mol. Psychiatry13(12), 1093–1101 (2008).
   PubMed Web of Science ®Google Scholar
• Jedema HP, Gianaros PJ, Greer PJ et al. Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission. Mol. Psychiatry15(5), 512–122 (2009).
   PubMedGoogle Scholar
• Benedetti F, Bernasconi A, Blasi V et al. Neural and genetic correlates of antidepressant response to sleep deprivation: a functional magnetic resonance imaging study of moral valence decision in bipolar depression. Arch. Gen. Psychiatry64(2), 179–187 (2007).
   PubMed Web of Science ®Google Scholar
• Pacheco J, Beevers CG, Benavides C, Mcgeary J, Stice E, Schnyer DM. Frontal-limbic white matter pathway associations with the serotonin transporter gene promoter region (5-HTTLPR ) polymorphism. J. Neurosci.29(19), 6229–6233 (2009).
   PubMed Web of Science ®Google Scholar
• Lemonde S, Turecki G, Bakish D et al. Impaired repression at a 5-hydroxytryptamine 1a receptor gene polymorphism associated with major depression and suicide. J. Neurosci.23(25), 8788–8799 (2003).
   PubMed Web of Science ®Google Scholar
• Neff CD, Abkevich V, Packer JC et al. Evidence for HTRLA and LHPP as interacting genetic risk factors in major depression. Mol. Psychiatry14(6), 621–630 (2009).
   PubMed Web of Science ®Google Scholar
• Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol.88(1), 17–31 (2009).
   PubMed Web of Science ®Google Scholar
• Gross C, Zhuang X, Stark K et al. Serotonin 1a receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature416(6879), 396–400 (2002).
   PubMed Web of Science ®Google Scholar
• Zanettini C, Carola V, Lo Iacono L, Moles A, Gross C, D’amato FR. Postnatal handling reverses social anxiety in serotonin receptor 1a knockout mice. Genes Brain Behav.9(1), 26–32 (2010).
   PubMedGoogle Scholar
• Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int. J. Neuropsychopharmacol.7(4), 501–506 (2004).
   PubMed Web of Science ®Google Scholar
• Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology31(8), 1745–1749 (2006).
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Wakeno M et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet.150B(1), 115–123 (2009).
   PubMed Web of Science ®Google Scholar
• Baune BT, Hohoff C, Roehrs T, Deckert J, Arolt V, Domschke K. Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression? Neurosci. Lett.436(2), 111–115 (2008).
   PubMed Web of Science ®Google Scholar
• Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J. Psychopharmacol.19(2), 166–172 (2005).
   PubMed Web of Science ®Google Scholar
• Anttila S, Huuhka K, Huuhka M et al. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J. Neural. Transm.114(8), 1065–1068 (2007).
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, Mcgrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry9(9), 879–889 (2004).
   PubMed Web of Science ®Google Scholar
• Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int. J. Neuropsychopharmacol.7(4), 453–460 (2004).
   PubMed Web of Science ®Google Scholar
• Levin GM, Bowles TM, Ehret MJ et al. Assessment of human serotonin 1a receptor polymorphisms and SSRI responsiveness. Mol. Diagn. Ther.11(3), 155–160 (2007).
   PubMed Web of Science ®Google Scholar
• Lin E, Chen PS, Chang HH et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry33(7), 1167–1172 (2009).
   PubMed Web of Science ®Google Scholar
• Fakra E, Hyde LW, Gorka A et al. Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. Arch. Gen. Psychiatry66(1), 33–40 (2009).
   PubMed Web of Science ®Google Scholar
• Lee BT, Ham BJ. Serotonergic genes and amygdala activity in response to negative affective facial stimuli in korean women. Genes Brain Behav.7(8), 899–905 (2008).
   PubMed Web of Science ®Google Scholar
• Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet.103(3), 273–279 (1998).
   PubMed Web of Science ®Google Scholar
• Cusin C, Serretti A, Zanardi R et al. Influence of monoamine oxidase a and serotonin receptor 2a polymorphisms in SSRI antidepressant activity. Int. J. Neuropsychopharmacol.5(1), 27–35 (2002).
   PubMed Web of Science ®Google Scholar
• Muller DJ, Schulze TG, Macciardi F et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase a promoter. Pharmacopsychiatry35(4), 157–158 (2002).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Naito S, Takahashi H et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in japanese patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry26(7–8), 1279–1283 (2002).
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology30(9), 1719–1723 (2005).
   PubMed Web of Science ®Google Scholar
• Lee BT, Ham BJ. Monoamine oxidase A-UVNTR genotype affects limbic brain activity in response to affective facial stimuli. Neuroreport19(5), 515–519 (2008).
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Buckholtz JW, Kolachana B et al. Neural mechanisms of genetic risk for impulsivity and violence in humans. Proc. Natl Acad. Sci. USA103(16), 6269–6274 (2006).
   PubMed Web of Science ®Google Scholar
• Cerasa A, Gioia MC, Labate A et al.Mao a vntr polymorphism and variation in human morphology: a VBM study. Neuroreport19(11), 1107–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Buckholtz JW, Callicott JH, Kolachana B et al. Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Mol. Psychiatry13(3), 313–324 (2008).
   PubMed Web of Science ®Google Scholar
• Dannlowski U, Ohrmann P, Konrad C et al. Reduced amygdala–prefrontal coupling in major depression: association with maoa genotype and illness severity. Int. J. Neuropsychopharmacol.12(1), 11–22 (2009).
   PubMed Web of Science ®Google Scholar
• Craddock N, Owen MJ, O’Donovan MC. The catechol-O -methyl transferase (COMT ) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol. Psychiatry11(5), 446–458 (2006).
   PubMed Web of Science ®Google Scholar
• Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-O -methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry60(2), 141–151 (2006).
   PubMed Web of Science ®Google Scholar
• Krugel LK, Biele G, Mohr PN, Li SC, Heekeren HR. Genetic variation in dopaminergic neuromodulation influences the ability to rapidly and flexibly adapt decisions. Proc. Natl Acad. Sci. USA106(42), 17951–17956 (2009).
   PubMed Web of Science ®Google Scholar
• Stein DJ. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry. CNS Spectr.13(7), 561–565 (2008).
   PubMed Web of Science ®Google Scholar
• Baune BT, Hohoff C, Berger K et al. Association of the COMT Val158Met variant with antidepressant treatment response in major depression. Neuropsychopharmacology33(4), 924–932 (2008).
   PubMed Web of Science ®Google Scholar
• Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E. The catechol-O -methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl.)203(1), 155–160 (2009).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Higuchi H, Takahashi H et al. Influence of the tyrosine hydroxylase Val81Met polymorphism and catechol-O -methyltransferase Val158Met polymorphism on the antidepressant effect of milnacipran. Hum. Psychopharmacol.23(2), 121–128 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, Chen TJ. Sexually dimorphic effect of catechol-O -methyltransferase Val158Met polymorphism on clinical response to fluoxetine in major depressive patients. J. Affect. Disord.113(1–2), 183–187 (2009).
   PubMed Web of Science ®Google Scholar
• Szegedi A, Rujescu D, Tadic A et al. The catechol-O -methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J.5(1), 49–53 (2005).
   PubMed Web of Science ®Google Scholar
• Arias B, Serretti A, Lorenzi C, Gasto C, Catalan R, Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to ssris in depressive patients of european origin. J. Affect. Disord.90(2–3), 251–256 (2006).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O -methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol. Psychiatry65(9), 785–791 (2009).
   PubMed Web of Science ®Google Scholar
• Secher A, Bukh J, Bock C et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int. Clin. Psychopharmacol.24(4), 199–203 (2009).
   PubMed Web of Science ®Google Scholar
• Taylor WD, Zuchner S, Payne ME et al. The COMT Val158Met polymorphism and temporal lobe morphometry in healthy adults. Psychiatry Res.155(2), 173–177 (2007).
   PubMed Web of Science ®Google Scholar
• Cerasa A, Gioia MC, Labate A, Liguori M, Lanza P, Quattrone A. Impact of catechol-O -methyltransferase Val(108/158)Met genotype on hippocampal and prefrontal gray matter volume. Neuroreport19(4), 405–408 (2008).
   PubMed Web of Science ®Google Scholar
• Ehrlich S, Morrow EM, Roffman JL et al. The COMT Val108/158Met polymorphism and medial temporal lobe volumetry in patients with schizophrenia and healthy adults. Neuroimage DOI: 10.1016/j.neuroimage.2009.12.046 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Williams LM, Gatt JM, Grieve SM et al. COMT Val(108/158)Met polymorphism effects on emotional brain function and negativity bias. Neuroimage (2010).
   Google Scholar
• Smolka MN, Schumann G, Wrase J et al. Catechol-O -methyltransferase Val158Met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J. Neurosci.25(4), 836–842 (2005).
   PubMed Web of Science ®Google Scholar
• Drabant EM, Hariri AR, Meyer-Lindenberg A et al. Catechol O -methyltransferase Val158Met genotype and neural mechanisms related to affective arousal and regulation. Arch. Gen. Psychiatry63(12), 1396–1406 (2006).
   PubMed Web of Science ®Google Scholar
• Kempton MJ, Haldane M, Jogia J et al. The effects of gender and COMT Val158Met polymorphism on fearful facial affect recognition: a fMRI study. Int. J. Neuropsychopharmacol.12(3), 371–381 (2009).
   PubMed Web of Science ®Google Scholar
• Pomarol-Clotet E, Fatjo-Vilas M, Mckenna PJ et al. COMT Val158Met polymorphism in relation to activation and de-activation in the prefrontal cortex: a study in patients with schizophrenia and healthy subjects. Neuroimage DOI: 10.1016/j.neuroimage.2010.04.018 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Bishop SJ, Cohen JD, Fossella J, Casey BJ, Farah MJ. COMT genotype influences prefrontal response to emotional distraction. Cogn. Affect. Behav. Neurosci.6(1), 62–70 (2006).
   PubMed Web of Science ®Google Scholar
• Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. Variation in dopamine genes influences responsivity of the human reward system. Proc. Natl Acad. Sci. USA106(2), 617–622 (2009).
   PubMed Web of Science ®Google Scholar
• Krach S, Jansen A, Krug A et al.COMT genotype and its role on hippocampal-prefrontal regions in declarative memory. Neuroimage DOI: 10.1016/j.neuroimage.2009.12.090 (2010).
   Google Scholar
• Honea R, Verchinski BA, Pezawas L et al. Impact of interacting functional variants in COMT on regional gray matter volume in human brain. Neuroimage45(1), 44–51 (2009).
   PubMed Web of Science ®Google Scholar
• Ohnishi T, Hashimoto R, Mori T et al. The association between the Val158Met polymorphism of the catechol-O -methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain129(Pt 2), 399–410 (2006).
   PubMedGoogle Scholar
• Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat. Rev. Neurosci.6(8), 603–614 (2005).
   PubMed Web of Science ®Google Scholar
• Hu Y, Russek SJ. BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. J. Neurochem.105(1), 1–17 (2008).
   PubMed Web of Science ®Google Scholar
• Stein DJ, Daniels WM, Savitz J, Harvey BH. Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology. CNS Spectr.13(11), 945–949 (2008).
   PubMed Web of Science ®Google Scholar
• Kozisek ME, Middlemas D, Bylund DB. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol. Ther.117(1), 30–51 (2008).
   PubMed Web of Science ®Google Scholar
• Castren E. Is mood chemistry? Nat. Rev. Neurosci.6(3), 241–246 (2005).
   PubMed Web of Science ®Google Scholar
• Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol. Psychiatry12(12), 1079–1088 (2007).
   PubMed Web of Science ®Google Scholar
• Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat. Neurosci.10(9), 1089–1093 (2007).
   PubMed Web of Science ®Google Scholar
• Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci.9(4), 519–525 (2006).
   PubMed Web of Science ®Google Scholar
• Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch. Gen. Psychiatry66(5), 488–497 (2009).
   PubMed Web of Science ®Google Scholar
• Egan MF, Kojima M, Callicott JH et al. The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell112(2), 257–269 (2003).
   PubMed Web of Science ®Google Scholar
• Chen L, Lawlor DA, Lewis SJ et al. Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet.147B(6), 814–821 (2008).
   PubMed Web of Science ®Google Scholar
• Verhagen M, Van Der Meij A, van Deurzen PA et al. Meta-analysis of the VDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol. Psychiatry15(3), 260–271 (2010).
   PubMed Web of Science ®Google Scholar
• Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM et al. Meta-analyses of genetic studies on major depressive disorder. Mol. Psychiatry13(8), 772–785 (2008).
   PubMed Web of Science ®Google Scholar
• Frustaci A, Pozzi G, Gianfagna F, Manzoli L, Boccia S. Meta-analysis of the brain-derived neurotrophic factor gene (BDNF ) Val66Met polymorphism in anxiety disorders and anxiety-related personality traits. Neuropsychobiology58(3–4), 163–170 (2008).
   PubMed Web of Science ®Google Scholar
• Saarelainen T, Hendolin P, Lucas G et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci.23(1), 349–357 (2003).
   PubMed Web of Science ®Google Scholar
• Wilkie MJ, Smith D, Reid IC et al. A splice site polymorphism in the γ-protein β subunit influences antidepressant efficacy in depression. Pharmacogenet. Genomics17(3), 207–215 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Higuchi H, Kamata M et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J. Psychopharmacol.21(6), 650–656 (2007).
   PubMed Web of Science ®Google Scholar
• Gratacos M, Soria V, Urretavizcaya M et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J.8(2), 101–112 (2008).
   PubMed Web of Science ®Google Scholar
• Rajewska-Rager A, Skibinska M, Szczepankiewicz A et al. [Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression]. Psychiatr. Pol.42(6), 915–923 (2008).
   PubMedGoogle Scholar
• Domschke K, Lawford B, Laje G et al. Brain-derived neurotrophic factor (BDNF ) gene: no major impact on antidepressant treatment response. Int. J. Neuropsychopharmacol.13(1), 93–101 (2010).
   PubMed Web of Science ®Google Scholar
• Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res.1118(1), 176–182 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am. J. Med. Genet. B Neuropsychiatr. Genet.123B(1), 19–22 (2003).
   PubMed Web of Science ®Google Scholar
• Masui T, Hashimoto R, Kusumi I et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in japanese patients with bipolar disorder. Psychiatr. Genet.16(2), 49–50 (2006).
   PubMedGoogle Scholar
• Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur. Neuropsychopharmacol. DOI: 10.1016/j.euroneuro.2009.12.005 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Chen ZY, Jing D, Bath KG et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science314(5796), 140–143 (2006).
   PubMed Web of Science ®Google Scholar
• Frodl T, Schule C, Schmitt G et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch. Gen. Psychiatry64(4), 410–416 (2007).
   PubMed Web of Science ®Google Scholar
• Matsuo K, Walss-Bass C, Nery FG et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology34(8), 1904–1913 (2009).
   PubMed Web of Science ®Google Scholar
• Pezawas L, Verchinski BA, Mattay VS et al. The brain-derived neurotrophic factor Val66Met polymorphism and variation in human cortical morphology. J. Neurosci.24(45), 10099–10102 (2004).
   PubMed Web of Science ®Google Scholar
• Schofield PR, Williams LM, Paul RH et al. Disturbances in selective information processing associated with the BDNF Val66Met polymorphism: evidence from cognition, the p300 and fronto-hippocampal systems. Biol. Psychol.80(2), 176–188 (2009).
   PubMed Web of Science ®Google Scholar
• Montag C, Weber B, Fliessbach K, Elger C, Reuter M. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression. Psychol. Med.39(11), 1831–1839 (2009).
   PubMed Web of Science ®Google Scholar
• Chepenik LG, Fredericks C, Papademetris X et al. Effects of the brain-derived neurotrophic growth factor Val66Met variation on hippocampus morphology in bipolar disorder. Neuropsychopharmacology34(4), 944–951 (2009).
   PubMed Web of Science ®Google Scholar
• Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta JK. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol. Psychiatry59(9), 812–815 (2006).
   PubMed Web of Science ®Google Scholar
• Szeszko PR, Lipsky R, Mentschel C et al. Brain-derived neurotrophic factor Val66Met polymorphism and volume of the hippocampal formation. Mol. Psychiatry10(7), 631–636 (2005).
   PubMed Web of Science ®Google Scholar
• Jessen F, Schuhmacher A, Von Widdern O et al. No association of the Val66Met polymorphism of the brain-derived neurotrophic factor with hippocampal volume in major depression. Psychiatr. Genet.19(2), 99–101 (2009).
   PubMed Web of Science ®Google Scholar
• Koolschijn PC, van Haren NE, Bakker SC, Hoogendoorn ML, Pol HE, Kahn RS. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus DOI: 10.1002/hipo.20699 (2009) (Epub ahead of print).
   Google Scholar
• Joffe RT, Gatt JM, Kemp AH et al. Brain derived neurotrophic factor Val66Met polymorphism, the five factor model of personality and hippocampal volume: implications for depressive illness. Hum. Brain Mapp.30(4), 1246–1256 (2009).
   PubMed Web of Science ®Google Scholar
• Hashimoto R, Moriguchi Y, Yamashita F et al. Dose-dependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity. Neurosci. Res.61(4), 360–367 (2008).
   PubMed Web of Science ®Google Scholar
• Hariri AR, Goldberg TE, Mattay VS et al. Brain-derived neurotrophic factor Val66Met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci.23(17), 6690–6694 (2003).
   PubMed Web of Science ®Google Scholar
• Monteggia LM, Barrot M, Powell CM et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl Acad. Sci. USA101(29), 10827–10832 (2004).
   PubMed Web of Science ®Google Scholar
• Heldt SA, Stanek L, Chhatwal JP, Ressler KJ. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol. Psychiatry12(7), 656–670 (2007).
   PubMed Web of Science ®Google Scholar
• Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol. Psychiatry63(7), 642–649 (2008).
   PubMed Web of Science ®Google Scholar
• Sublette ME, Baca-Garcia E, Parsey RV et al. Effect of BDNF Val66Met polymorphism on age-related amygdala volume changes in healthy subjects. Prog. Neuropsychopharmacol. Biol. Psychiatry32(7), 1652–1655 (2008).
   PubMedGoogle Scholar
• Nemoto K, Ohnishi T, Mori T et al. The Val66Met polymorphism of the brain-derived neurotrophic factor gene affects age-related brain morphology. Neurosci. Lett.397(1–2), 25–29 (2006).
   PubMed Web of Science ®Google Scholar
• Gasic GP, Smoller JW, Perlis RH et al. BDNF, relative preference, and reward circuitry responses to emotional communication. Am. J. Med. Genet. B. Neuropsychiatr. Genet.150B(6), 762–781 (2009).
   PubMed Web of Science ®Google Scholar
• Soliman F, Glatt CE, Bath KG et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science327(5967), 863–866 (2010).
   PubMed Web of Science ®Google Scholar
• Montag C, Reuter M, Newport B, Elger C, Weber B. The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study. Neuroimage42(4), 1554–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Logothetis NK. What we can do and what we cannot do with fMRI. Nature453(7197), 869–878 (2008).
   PubMed Web of Science ®Google Scholar
• Riley BP, Mcguffin P. Linkage and associated studies of schizophrenia. Am. J. Med. Genet.97(1), 23–44 (2000).
   PubMed Web of Science ®Google Scholar
• Menzel S. Genetic and molecular analyses of complex metabolic disorders: genetic linkage. Ann. N. Y. Acad. Sci.967, 249–257 (2002).
   PubMedGoogle Scholar
• Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science322(5903), 881–888 (2008).
   PubMed Web of Science ®Google Scholar
• Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet.33(2), 177–182 (2003).
   PubMed Web of Science ®Google Scholar
• Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet. Med.4(2), 45–61 (2002).
   PubMed Web of Science ®Google Scholar
• Garriock HA, Hamilton SP. Genetic studies of drug response and side effects in the STAR*D study, part 1. J. Clin. Psychiatry70(8), 1186–1187 (2009).
   PubMedGoogle Scholar
• Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature455(7215), 894–902 (2008).
   PubMed Web of Science ®Google Scholar
• Lesch KP. Gene-environment interaction and the genetics of depression. J. Psychiatry Neurosci.29(3), 174–184 (2004).
   PubMed Web of Science ®Google Scholar
• Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry160(4), 636–645 (2003).
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat. Rev. Neurosci.7(10), 818–827 (2006).
   PubMed Web of Science ®Google Scholar
• Flint J, Munafo MR. The endophenotype concept in psychiatric genetics. Psychol. Med.37(2), 163–180 (2007).
   PubMed Web of Science ®Google Scholar
• Mier D, Kirsch P, Meyer-Lindenberg A. Neural substrates of pleiotropic action of genetic variation in COMT : a meta-analysis. Mol. Psychiatry DOI: 0.1038/mp.2009.36 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Huettel SA, Song AW, Mccarthy G. Functional Magnetic Resoncance Imaging. Sinauer Associates, Inc., MA. USA (2009).
   Google Scholar
• Meyer-Lindenberg A, Nicodemus KK, Egan MF, Callicott JH, Mattay V, Weinberger DR. False positives in imaging genetics. Neuroimage40, 655–661 (2008).
   PubMed Web of Science ®Google Scholar
• Frodl T, Meisenzahl EM, Zetzsche T et al. Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol. Psychiatry53(4), 338–344 (2003).
   PubMed Web of Science ®Google Scholar
• Kronmuller KT, Schroder J, Kohler S et al. Hippocampal volume in first episode and recurrent depression. Psychiatry Res.174(1), 62–66 (2009).
   PubMedGoogle Scholar
• Neumeister A, Wood S, Bonne O et al. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol. Psychiatry57(8), 935–937 (2005).
   PubMed Web of Science ®Google Scholar
• Burmeister M, Mcinnis MG, Zollner S. Psychiatric genetics: progress amid controversy. Nat. Rev. Genet.9(7), 527–540 (2008).
   PubMed Web of Science ®Google Scholar
• Della Pasqua O, Santen GW, Danhof M. The missing link between clinical endpoints and drug targets in depression. Trends Pharmacol. Sci.31(4), 144–152 (2010).
   PubMed Web of Science ®Google Scholar
• Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry59(12), 1116–1127 (2006).
   PubMed Web of Science ®Google Scholar
• Pezawas L, Meyer-Lindenberg A, Goldman AL et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol. Psychiatry13(7), 709–716 (2008).
   PubMed Web of Science ®Google Scholar
• Canli T, Congdon E, Todd Constable R, Lesch KP. Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on neural correlates of affective processing. Biol. Psychol.79(1), 118–125 (2008).
   PubMed Web of Science ®Google Scholar
• Gatt JM, Nemeroff CB, Dobson-Stone C et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol. Psychiatry14(7), 681–695 (2009).
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Nichols T, Callicott JH et al. Impact of complex genetic variation in COMT on human brain function. Mol. Psychiatry11(9), 867–877, 797 (2006).
   PubMed Web of Science ®Google Scholar
• Ising M, Lucae S, Binder EB et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry66(9), 966–975 (2009).
   PubMed Web of Science ®Google Scholar
• Garriock HA, Kraft JB, Shyn SI et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry67(2), 133–138 (2010).
   PubMed Web of Science ®Google Scholar
• Mcmahon FJ, Akula N, Schulze TG et al. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat. Genet.42(2), 128–131 (2010).
   PubMed Web of Science ®Google Scholar
• Shyn SI, Shi J, Kraft JB et al. Novel loci for major depression identified by genome-wide association study of sequenced treatment alternatives to relieve depression and meta-analysis of three studies. Mol. Psychiatry DOI: 10.1038/mp.2009.125 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Shi J, Potash JB, Knowles JA et al. Genome-wide association study of recurrent early-onset major depressive disorder. Mol. Psychiatry DOI: 10.1038/mp.2009.124 (2010) (Epub ahead of print).
   Google Scholar
• Muglia P, Tozzi F, Galwey NW et al. Genome-wide association study of recurrent major depressive disorder in two european case–control cohorts. Mol. Psychiatry15(6), 589–601 (2010).
   PubMed Web of Science ®Google Scholar
• Mcmahon FJ. Pioneering first steps and cautious conclusions. Biol. Psychiatry67(2), 99–100 (2010).
   PubMedGoogle Scholar
• Esslinger C, Walter H, Kirsch P et al. Neural mechanisms of a genome-wide supported psychosis variant. Science324(5927), 605 (2009).
   PubMed Web of Science ®Google Scholar
• Walter H, Schnell K, Erk S et al. Effects of a genome-wide supported psychosis risk variant on neural activation during a theory-of-mind task. Mol. Psychiatry DOI: 10.1038/mp.2010.18 (2010) (Epub ahead of print).
   Google Scholar
• Stein JL, Hua X, Lee S et al. Voxelwise genome-wide association study (vGWAS). Neuroimage DOI: 10.1016/j.neuroimage.2010.02.032 (2010) (Epub ahead of print).
   Google Scholar